Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344589 | 0.83 | KCNQ1 (0.36) | P2RX7POLBAOC3SMN1; SMN2ALDH1A1 | |
| SCHEMBL4345303 | 0.83 | NPC1 (0.39) | POLBLMNAAOC3NPC1SMN1; SMN2 | |
| SCHEMBL700177 | 0.79 | NPC1 (0.43) | POLBLMNAPKMNPC1SMN1; SMN2 | |
| SCHEMBL3454349 | 0.76 | NPC1 (0.43) | LMNAPKMAOC3NPC1SMN1; SMN2 | |
| SCHEMBL10246158 | 0.75 | NPC1 (0.44) | POLBLMNAPKMNPC1SMN1; SMN2 | |
| SCHEMBL4345405 | 0.73 | HCRTR1 (0.36) | P2RX7LMNAAOC3NPC1 | |
| SCHEMBL3442720 | 0.72 | NPC1 (0.46) | POLBLMNAPKMNPC1SMN1; SMN2 | |
| SCHEMBL3442722 | 0.72 | NPC1 (0.41) | POLBLMNAPKMNPC1PTGDR2 | |
| SCHEMBL4356188 | 0.72 | AVPR1A (0.36) | AOC3GAA | |
| SCHEMBL13673252 | 0.71 | NPC1 (0.46) | LMNAPKMNPC1PTGDR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | claimed |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | claimed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | BDKRB2, BDKRB1, TRPV1 | P2RX7 243/4885POLB 4558/4885LMNA 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.